Plus Therapeutics Q2 EPS $(0.59) Beats $(1.91) Estimate, Sales $1.85M Beat $790.00K Estimate
Portfolio Pulse from mahesh@benzinga.com
Plus Therapeutics reported Q2 losses of $(0.59) per share, beating the analyst consensus estimate of $(1.91) by 69.11%. This is an 83.61% increase over losses from the same period last year. The company also reported quarterly sales of $1.85 million, beating the analyst consensus estimate of $790.00 thousand by 134.68%.
August 14, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics reported better than expected Q2 results, with losses per share and sales beating analyst estimates.
Plus Therapeutics reported Q2 losses per share of $(0.59), which is better than the analyst consensus estimate of $(1.91). This is a significant improvement over the same period last year. Additionally, the company's quarterly sales of $1.85 million exceeded the analyst consensus estimate of $790.00 thousand. These better than expected results could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100